Screening MT1-MMP Activity and Inhibition in Three-Dimensional Tumor Spheroids

被引:2
作者
Knapinska, Anna M. M. [1 ,2 ]
Drotleff, Gary [1 ,2 ]
Chai, Cedric [2 ]
Twohill, Destiny [2 ]
Ernce, Alexa [2 ]
Tokmina-Roszyk, Dorota [2 ]
Grande, Isabella [2 ]
Rodriguez, Michelle [2 ]
Larson, Brad [3 ]
Fields, Gregg B. B. [2 ]
机构
[1] Alphazyme, Jupiter, FL 33458 USA
[2] Florida Atlantic Univ, Inst Human Hlth & Dis Intervent I HEALTH, Jupiter, FL 33458 USA
[3] Agilent Technol, Raleigh, NC 27606 USA
关键词
membrane type 1 matrix metalloproteinase; glioblastoma; spheroid; cell-based high-throughput screening; triple helix; collagen; FRET assay; TYPE-1; MATRIX-METALLOPROTEINASE; GROWTH-FACTOR; STEM-CELL; IN-VIVO; CANCER; ACTIVATION; BRAIN; EXPRESSION; GLIOMAS; GLIOBLASTOMAS;
D O I
10.3390/biomedicines11020562
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Membrane type 1 matrix metalloproteinase (MT1-MMP) has been shown to be crucial for tumor angiogenesis, invasion, and metastasis, and thus MT1-MMP is a high priority target for potential cancer therapies. To properly evaluate MT1-MMP inhibitors, a screening protocol is desired by which enzyme activity can be quantified in a tumor microenvironment-like model system. In the present study, we applied a fluorogenic, collagen model triple-helical substrate to quantify MT1-MMP activity for tumor spheroids embedded in a collagen hydrogel. The substrate was designed to be MT1-MMP selective and to possess fluorescent properties compatible with cell-based assays. The proteolysis of the substrate correlated to glioma spheroid invasion. In turn, the application of either small molecule or protein-based MMP inhibitors reduced proteolytic activity and glioma spheroid invasion. The presence of MT1-MMP in glioma spheroids was confirmed by western blotting. Thus, spheroid invasion was dependent on MT1-MMP activity, and inhibitors of MT1-MMP and invasion could be conveniently screened in a high-throughput format. The combination of the fluorogenic, triple-helical substrate, the three-dimensional tumor spheroids embedded in collagen, and Hit-Pick software resulted in an easily adaptable in vivo-like tumor microenvironment for rapidly processing inhibitor potential for anti-cancer use.
引用
收藏
页数:17
相关论文
共 80 条
[1]   Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity [J].
Albright, CF ;
Graciani, N ;
Han, W ;
Yue, E ;
Stein, R ;
Lai, ZH ;
Diamond, M ;
Dowling, R ;
Grimminger, L ;
Zhang, SY ;
Behrens, D ;
Musselman, A ;
Bruckner, R ;
Zhang, MZ ;
Jiang, X ;
Hu, D ;
Higley, A ;
DiMeo, S ;
Rafalski, M ;
Mandlekar, S ;
Car, B ;
Yeleswaram, S ;
Stern, A ;
Copeland, RA ;
Combs, A ;
Seitz, SP ;
Trainor, GL ;
Taub, R ;
Huang, P ;
Oliff, A .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) :751-760
[2]  
American Association of Neurological Surgeons, BRAIN TUM CLASS SYMP
[3]   Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy [J].
Ansari, Celina ;
Tikhomirov, Grigory A. ;
Hong, Su Hyun ;
Falconer, Robert A. ;
Loadman, Paul M. ;
Gill, Jason H. ;
Castaneda, Rosalinda ;
Hazard, Florette K. ;
Tong, Ling ;
Lenkov, Olga D. ;
Felsher, Dean W. ;
Rao, Jianghong ;
Daldrup-Link, Heike E. .
SMALL, 2014, 10 (03) :566-575
[4]   Matrix metalloproteinases:: New routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease [J].
Arroyo, A. G. ;
Genis, L. ;
Gonzalo, P. ;
Matias-Roman, S. ;
Pollan, A. ;
Galvez, B. G. .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (17) :1787-1802
[5]   Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases [J].
Atkinson, Jennifer M. ;
Falconer, Robert A. ;
Edwards, Dylan R. ;
Pennington, Caroline J. ;
Siller, Catherine S. ;
Shnyder, Steven D. ;
Bibby, Michael C. ;
Patterson, Laurence H. ;
Loadman, Paul M. ;
Gill, Jason H. .
CANCER RESEARCH, 2010, 70 (17) :6902-6912
[6]   Targeted delivery of a colchicine analogue provides synergy with ATR inhibition in cancer cells [J].
Barnieh, Francis M. ;
Morais, Goreti Ribeiro ;
Garland, Herbie ;
Loadman, Paul M. ;
Falconer, Robert A. .
BIOCHEMICAL PHARMACOLOGY, 2022, 201
[7]   Migration and invasion in brain neoplasms. [J].
Bolteus A.J. ;
Berens M.E. ;
Pilkington G.J. .
Current Neurology and Neuroscience Reports, 2001, 1 (3) :225-232
[8]   Antifibrinolytic Role of a Bee Venom Serine Protease Inhibitor That Acts as a Plasmin Inhibitor [J].
Choo, Young Moo ;
Lee, Kwang Sik ;
Yoon, Hyung Joo ;
Qiu, Yuling ;
Wan, Hu ;
Sohn, Mi Ri ;
Sohn, Hung Dae ;
Jin, Byung Rae .
PLOS ONE, 2012, 7 (02)
[9]   Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles [J].
Daldrup-Link, Heike E. .
MOLECULAR IMAGING, 2017, 16 :1-4
[10]   Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity [J].
de Andrade, Lucas Ferrari ;
Tay, Rong En ;
Pan, Deng ;
Luoma, Adrienne M. ;
Ito, Yoshinaga ;
Badrinath, Soumya ;
Tsoucas, Daphne ;
Franz, Bettina ;
May, Kenneth F., Jr. ;
Harvey, Christopher J. ;
Kobold, Sebastian ;
Pyrdol, Jason W. ;
Yoon, Charles ;
Yuan, Guo-Cheng ;
Hodi, F. Stephen ;
Dranoff, Glenn ;
Wucherpfennig, Kai W. .
SCIENCE, 2018, 359 (6383) :1537-+